Biosimilars have been on the market in Europe since 2007 but have had a larger impact on Amgen since 2019 as US exposure intensifies. Pressure on Prolia/Xgeva is coming in 2025. Amgen's pipeline had ...

What Happened: Grygiel's recent move involves selling 1,589 shares of Amgen. This information is documented in a Form 4 filing with the U.S. Securities and Exchange Commission on Friday. The total ...

Sandoz is to appeal a court decision preventing it from launching a cheaper biosimilar competitor to Amgen’s Enbrel (etanercept) inflammatory diseases drug in the US, three years after approval ...

Results include $1.2 billion of sales from rare disease products, driven by TEPEZZA, KRYSTEXXA, UPLIZNA, and TAVNEOS. Earnings reflect acquisition-related costs related to the Horizon acquisition.

A key part of Amgen’s strategy was to broaden the indications for those drugs it already owned, with Epogen successfully obtaining indications for anaemia in cancer patients, Enbrel broadening ...

Amgen AMGN reported fourth-quarter 2024 adjusted earnings of $5.31 per share, which beat the Zacks Consensus Estimate of ...

While you wait for the groundhog to make his determination this weekend, take some time to buff up your knowledge of ...

Amgen's dividend yield remains attractive, with a moderate payout ratio and strong free cash flow. Click here to see why AMGN ...

The second round of Medicare Part D price negotiations will feature two drugs familiar to rheumatologists — Ofev and Otezla — ...

Biosimilar competition continues to impose challenges, notably impacting legacy products like Neulasta and Enbrel. The sales ...

Script trends suggest Enbrel is tracking for a 16% year-over ... Wells says that while Amgen’s fiscal 2025 outlook could fall below expectations, the company’s Q4 “appears in line.” ...